NCT07762170 Success Rates and Safety of Steroid Injections in Managing Spinal and Sacro-Iliac Pain (CORTisone Injection Spine Study)
| NCT ID | NCT07762170 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Igor Wilderman. MD |
| Condition | Back Pain Lower Back |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2026-07-30 |
| Primary Completion | 2029-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 500 participants in total. It began in 2026-07-30 with a primary completion date of 2029-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to analyze the efficacy and safety of different kinds of steroid injections for back pain, comparing different steroids, dosages, locations (epidural, facet joints, nerve blocks), and also the difference between injections with steroids and local anesthetics, to optimize this treatment that is currently not standardized. The investigators will compare retrospectively and prospectively the efficacy of different injections in the same patients, using mainly a parameter called integral of pain relief, which combines the percentage of pain relief provided by a treatment and its duration over time, as well as improvements in functionality.
Eligibility Criteria
Inclusion Criteria: * \>18 years of age; * Diagnosis of lumbar, cervical, or thoracic pain with various etiologies; * Eligibility to receive steroid injections for back pain, including epidural, facet joints, or SIJ injections, or other injections (e.g., local anesthetics); * Being willing and able to provide NRS pain ratings and PROMIS functionality ratings before the intervention, and the same scores plus IPR, fIPR, and PGIC at various follow-up points after the intervention; * Provide written informed consent. Exclusion Criteria: * Diagnosis of dementia, Parkinson's disease or other cognitive impairments; * Congenital or acquired polyneuropathy; * Back surgery in the month before injection treatment or planned surgery in the subsequent 3 months; * Any clinically significant acute or chronic medical condition that in the judgment of Investigator may preclude injection in the epidural space or compromise patient safety, limit patient's ability to complete the study, and/or compromise the objectives of the study; * Participation in any other competing clinical study within 3 months prior to screening and during the study period.
Contact & Investigator
Igor Wilderman, MD
PRINCIPAL INVESTIGATOR
Canadian Centre for Clinical Trials
Frequently Asked Questions
Who can join the NCT07762170 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Back Pain Lower Back. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07762170 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07762170 currently recruiting?
Yes, NCT07762170 is actively recruiting participants. Contact the research team at iw@drwilderman.com for enrollment information.
Where is the NCT07762170 trial being conducted?
This trial is being conducted at Thornhill, Canada.
Who is sponsoring the NCT07762170 clinical trial?
NCT07762170 is sponsored by Igor Wilderman. MD. The principal investigator is Igor Wilderman, MD at Canadian Centre for Clinical Trials. The trial plans to enroll 500 participants.